arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT US Pharma and Biotech Summit 2020

Resetting the Pharma Agenda for a Post-COVID-19 World

New York |
Speakers include:
Robert Bradway

Robert Bradway


Stephen M. Hahn

Stephen M. Hahn

U.S. Food & Drug Administration

Jessica Mega

Jessica Mega

Verily Life Sciences


FT US Pharma and Biotech Summit - Postponed to 29 - 30 September 2020

The coronavirus pandemic has placed the pharma and biotech industries firmly in the spotlight. From R&D to the embrace of digital technologies and collaborations, no area of the business remains untouched. Meanwhile, innovations in burgeoning research areas to include cell and gene therapies will only increase as pharma reignites its drive for growth in a more challenging economic environment.

Through the lens of COVID-19 and the industry response the crisis, the 2nd edition of FT US Pharma and Biotech Summit will provide a fresh perspective on the crucial issues impacting the pharma and biotech industries. Senior industry leaders will share their insights, ideas and expertise on topics such as the pharma pricing and politics, the expansion of real-world evidence and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.

fallback Add to my Calendar 09/29/2020 08:15:0009/29/2020 17:00:00trueFT US Pharma and Biotech Summit 2020FT US Pharma and Biotech Summit - Postponed to 29 - 30 September 2020The coronavirus pandemic has placed the pharma and biotech industries firmly in the spotlight. From R&D to the embrace of digital technologies and collaborations, no area of the business remains untouched. Meanwhile, innovations in burgeoning research areas to include cell and gene therapies will only increase as pharma reignites its drive for growth in a more challenging economic environment.Through the lens of COVID-19 and the industry response the crisis, the 2nd edition of FT US Pharma and Biotech Summit will provide a fresh perspective on the crucial issues impacting the pharma and biotech industries. Senior industry leaders will share their insights, ideas and expertise on topics such as the pharma pricing and politics, the expansion of real-world evidence and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.FT-US-Pharma-and-Biotech-Summit-20208293506cf8d2a97a86478592a0334806MM/DD/YYYY

International Women's Day Interview with Mary Rozenman, Insitro

Read now

New download - Trends and growth opportunities

New download - insights, trends and growth opportunities

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

For more information about how we use your data please refer to our privacy and cookie policies.

Invites and offers from the FT

Receive exclusive personalised events invitations, carefully-curated offers, future speaking engagements and promotions from Financial Times Live

Thank you for submitting your details. Please download the event brochure.


2019 Conference Highlights

Hannah Kuchler



What attendees had to say about their 2019 experience

“This is a must-attend meeting for the healthcare industry. A thoughtfully curated agenda with industry leaders, emerging disruptors, patients and regulators makes this one of the top health events of the year.”

“The sessions highlighted the complexities that we have in the US healthcare system and the various viewpoints that we should all consider.”

“By far the most interesting summit to date. Basically stayed on topic and highlighted different views and perspectives effectively...”


Speakers (31)

Robert Bradway

Robert Bradway

Chairman and CEO
Stephen M. Hahn

Stephen M. Hahn

U.S. Food & Drug Administration

Stephen Hahn, who was sworn in as the 24th Commissioner of Food and Drugs on December 17, 2019. Dr Hahn is a dedicated clinician, having trained in both medical oncology and radiation oncology. In his previous leadership roles, he has always carefully balanced executive management with clinical time to continue to serve oncology patients, his true passion.

Prior to joining the FDA, Dr Hahn served as the chief medical executive at The University of Texas MD Anderson Cancer Center, a facility that cares for more than 140,000 patients a year. Before joining MD Anderson, he served as Chair of the Radiation Oncology department at the University of Pennsylvania’s Perelman School of Medicine from 2005 to 2014.

Dr Hahn earned the rank of Commander in the U.S. Public Health Service Commissioned Corps while at the National Institute of Health’s National Cancer Institute, where he also completed a fellowship in medical oncology and a residency in radiation oncology. He also a completed residency in internal medicine at University of California, San Francisco.

Jessica Mega

Jessica Mega

Chief Medical and Scientific Officer
Verily Life Sciences
Alexander Hardy

Alexander Hardy


Alexander Hardy became Genentech’s Chief Executive Officer on March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Mr Hardy led cross-functional teams to develop and launch new medicines and indications in more than 100 countries worldwide. He also co-chaired Roche’s late-stage portfolio committee, with direct accountability for new formulations and devices, geographic expansion, and post-marketing investments. From 2014 to 2016, Mr Hardy was head of Asia Pacific for Roche Pharmaceuticals, overseeing 19 countries and more than 6,000 employees. Prior to this, starting in 2005 he held several senior management positions at Genentech, including heading patient access services and leading commercial operations for a range of medicines and therapeutic areas from HER2-positive cancer to influenza and neuroscience. Prior to Genentech, Mr Hardy held leadership positions at Novartis as head of market access for Europe, country head for Denmark, and business unit head and director of strategic planning and new product development in the UK. Mr Hardy completed his undergraduate education at Cambridge University in the UK  and earned his MBA at the University of Michigan. 


Margaret Anderson

Margaret Anderson

Managing Director
Peter  Bach

Peter Bach

Director, Center for Health Policy and Outcomes
Memorial Sloan Kettering Cancer Center

Dr Peter Bach is a physician, epidemiologist, writer, and recognized expert in healthcare policy whose work has been regularly featured in major scientific and lay press outlets such as the NEJM, JAMA, and the New York Times. He is the Director, and currently holds the titles of Member in the Department of Epidemiology and Biostatistics and Attending Physician in the Department of Medicine at Memorial Sloan Kettering. He has also been a Senior Scholar at the International Agency for Research on Cancer since 2008.

Dr Bach is a member of the Institute of Medicine’s Board on Health Care Services and National Cancer Policy Forum and the Committee on Performance Measurement of the National Committee on Quality Assurance; he is also the Chair of the Center for Medicare and Medicaid Services Technical Expert Panel, which works to develop quality measures for PPS-exempt cancer hospitals. He has been inducted into the American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He also serves on the Board of Advisors of the University of Michigan Cancer Center and on the World Economic Forum, and is a member of the Clinton Global Initiative. Previously, Dr Bach was a member of the Institute of Medicine’s Committee on Geographic Variations and the Chair of a multi-society evidence-based guideline development committee on lung cancer screening. He also served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006

Dr Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar.

Liz Barrett

Liz Barrett

UroGen Pharma

Liz Barrett is a highly regarded industry leader with extensive experience in leading business organizations and Fortune 500 pharmaceutical companies. Prior to UroGen, she was CEO of Novartis Oncology and a member of the Novartis Executive Committee. She previously served as Global President of Oncology at Pfizer Inc., where she held numerous leadership positions, including President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and President of United States Oncology .Prior to Pfizer, Ms Barrett held positions at Cephalon Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson & Johnson. She started her career at Kraft Food Groups, Inc.

Ms Barrett holds an MBA from Saint Joseph’s University and a Bachelor of Science degree from the University of Louisiana.

Florian Brand

Florian Brand

Founder and CEO
ATAI Life Sciences
Rich Carter

Rich Carter

Vice President, Chief Digital Officer
Eli Lilly and Company
Shabbir Dahod

Shabbir Dahod

President and CEO
Tom Fezza

Tom Fezza

Principal, Life Sciences Strategy Practice

Tom Fezza is a Principal in Deloitte’s Life Sciences Strategy practice based in New York. He has over 20 years of consulting experience working with life sciences and health care companies. His areas of expertise include strategic planning, growth, R&D and therapeutic area strategy development, as well as operating model redesign.

Mr Fezza’s experiences are diverse, and range from defining and evaluating new business models, enterprise growth strategies, and commercialization strategies to assessing the performance and value of R&D organizations. He has worked with senior pharmaceutical, biotech, and health tech start-up leadership to successfully define and implement transformational strategies.  

Mr Fezza is a graduate of the United States Military Academy at West Point. He also holds an MBA from the Wharton School at the University of Pennsylvania.

Oren Frank

Oren Frank

Co-founder and CEO

Oren Frank is a Co-founder and the CEO of Talkspace, the leading online and mobile psychotherapy company that has made therapy accessible and affordable to people across the globe. In a day and age when mental health care is recognized as a global societal crisis, the effectiveness and
convenience Talkspace provides to those seeking to improve their mental health and well-being stands out. Under Oren’s leadership, Talkspace has so far helped more than 500,000 clients connect with licensed therapists — the vast majority of whom had no prior access. As an avid believer in the
power of innovation and technology to better society, Mr Frank founded Talkspace with his wife Roni in 2012, with the vision of “Therapy for all.” After experiencing the benefits of couples therapy earlier in their marriage, they launched Talkspace with the strong belief that mental health care is a moral
right, and everyone should have access to the support and value psychotherapy provides whenever the need or want arises.

Prior to Talkspace, Mr Frank was a successful senior marketing and advertising executive, mostly with McCann Erickson WorldWide, where he was recognized as a progressive creative strategist, and one of the leading voices in the new media-marketing world. Mr Frank maintains that Talkspace helps him redeem and repent for his years spent in advertising.

Bernard  Hamelin

Bernard Hamelin

Global Head of Medical Evidence Generation

Bernard Hamelin MD, MSc, MBA, is the Global Head of Medical Evidence Generation within the Medical Function at Sanofi, a global healthcare leader that discovers, develops and distributes therapeutic solutions for patients. In that role, he is responsible for delivering evidence required to demonstrate the value of Sanofi products, from early to late phase development. He also helps drive innovative and collaborative activities in order to engage with the changing healthcare landscape and to improve patient outcomes.  Dr Hamelin is a Medical Doctor who trained in Liver diseases and Gastroenterology in Paris from 1984 to 1991. He joined AstraZeneca in 1991 as responsible for Gastrointestinal (GI) clinical and medical affairs programs in the company’s French affiliate. From 1994 to 2001 Dr Hamelin occupied different clinical research roles based in Sweden (Goteborg) and in the USA (Philadelphia). He was the lead physician on the esomeprazole (Proton Pump Inhibitor) project and led the emerging GI global product team. In 2001, Dr Hamelin was appointed head of the French AstraZeneca affiliate Medical Affairs team, based in Rue-Malmaison. His team supported the successful launch of different products (incl. Crestor (statin), Symbicort (inhaled glucocorticosteroid), Arimidex (aromatase inhibitor).

Christopher Hansung Ko

Christopher Hansung Ko

President, CEO and Chairman of the Board
Samsung Bioepis

Christopher Hansung Ko is President, Chief Executive Officer and Chairman of the Board of Samsung Bioepis. Following his appointment as the CEO of Samsung Bioepis upon its establishment in Feb 2012, Dr Ko has led the company to become one of the leading biosimilar companies. With the company’s vision ‘Passion for Health’, Samsung Bioepis is working to fulfill the unmet needs of patients who cannot afford or access effective treatments, and will continue to do so through passion, utmost integrity and with constant innovation. Since joining Samsung in 2000, Dr Ko has held leadership positions with increasing responsibilities; from 2000 to 2007, he served as Vice President of the Bio & Health Lab at Samsung Advanced Institute of Technology (SAIT), the central research organization of Samsung. From 2007 to 2012, he served as Senior Vice President of the New Business Development Team and was responsible for advancing the new business initiatives in medical equipment, biopharmaceuticals and healthcare services. Prior to joining Samsung, Dr Ko served as CEO of Target Quest, a start-up biopharmaceutical company specializing in phage display. He also served as Vice President of Corporate Development at Dyax Corp after the company’s merger with Target Quest. Dr Ko holds a Bachelor’s degree in Biochemistry from University of California, Berkeley, a PhD in Molecular Genetics from Northwestern University, and completed his post-doctoral training at Stanford University.

Kimberly Haugstad

Kimberly Haugstad

Global Genes
Julia Hoffman

Julia Hoffman

Vice President, Behavioural Health Strategy
Natalie Kofler

Natalie Kofler

Editing Nature

Natalie Kofler is a trained molecular biologist and a leading voice in CRISPR and synthetic biology ethics. She advocates for equity in science and the inclusion of diverse perspectives in technology design and governance.  Her work has been highlighted by The Guardian, Nature, CBC radio, Pacific Standard Magazine, and National Geographic. She is an affiliated scholar of the Yale Interdisciplinary Center for Bioethics and the Solomon Center for Health Law and Policy at the Yale Law School. She teaches Environmental Ethics and Justice at Harvard Medical School and Yale University. She received her PhD in cellular, molecular, and medical biosciences and MS in human nutrition and metabolic studies from Columbia University and her BS in human anatomy and cell biology from McGill University. Dr. Kofler is currently the Levenick Resident Scholar at the Institute of Sustainability, Energy, and the Environment at the University of Illinois Urbana-Champaign and founder of Editing Nature, a global initiative to steer responsible development and deployment of environmental genetic technologies. 

Ofer Leidner

Ofer Leidner

President and Co-Founder
Happify Health

An experienced entrepreneur and business leader, Ofer Leidner co-founded and built several digital media businesses, most recently iPlay/Oberon Media, a leading casual downloadable games company where he held several executive leadership roles. Mr Leidner has also served as Co-Founder and President of Gate42 Technologies, a software start-up in the customer relations management space. Earlier in his career, he served as an investment manager at an early stage seed fund and as a management consultant in the strategy practice of Trigger Consulting, a leading firm in Israel. Mr Leidner holds an MBA. in Finance and a BA in Economics and Information Technologies, both from Tel Aviv University.

William Lewis

William Lewis

Chairman and Chief Executive Officer

William Lewis joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became Chairman of the board of directors in 2018. Mr Lewis is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the US and Europe. He also previously worked for the US government. Mr Lewis holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University.

Sandy Macrae

Sandy Macrae

President and Chief Executive Officer
Sangamo Therapeutics

Sandy Macrae, MB, ChB, PhD, has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry, most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr Macrae held roles of increasing responsibility at GlaxoSmithKline (GSK), including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr Macrae received his BS in Pharmacology and his MB, ChB. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr Macrae also earned his PhD in Molecular Genomics at King’s College, Cambridge.

Husseini Manji

Husseini Manji

Global Therapeutic Head for Neuroscience
Janssen Research & Development

Husseini Manji, MD, FRCPC is Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, one of the Johnson & Johnson pharmaceutical companies. Dr Manji was previously Chief of the Laboratory of Molecular Pathophysiology & Experimental Therapeutics at the National Institutes of Health (NIH)and Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world.The major focus of Dr Manji’s research is the investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. His work has helped to conceptualize these illnesses as genetically-influenced disorders of synaptic and neural plasticity and has led to the investigation of novel therapeutics for refractory patients. Most recently, his work contributed to the FDA approval of esketamine for treatment-resistant depression, an agent with the first novel mechanism of action in 60 years.  Dr Manji has been inducted into the National Academy of Medicine (formerly IOM) and the World Economic Forum (WEF) Global Future Councils. He has received a number of prestigious awards, including the NIMH Director's Career Award for Significant Scientific Achievement, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the DBSA Klerman Senior Distinguished Researcher Award, the American Federation for Aging Research Award of Distinction, and PhRMA’s Research & Hope Award for Excellence in Biopharmaceutical Research. He was also recognized as one of 14 inaugural “Health Heroes” by Oprah magazine. 

George McMillan

George McMillan

Chief Commercial Officer

George McMillan is Chief Commercial Officer of ICON. Mr McMillan joined ICON in 2012 as Executive Vice President of Finance Operations, a position he held until he was appointed to his current position in March 2017. Prior to ICON, Mr McMillan held senior executive positions in a variety of service and consulting companies, most recently as CFO of PharmaNet Development Group. He also served as CEO of Palladium Group, a global leader in corporate performance management software and consulting; CFO and CEO of CMGI, the internet holding company, for which he was named Mass HighTech Turnaround CEO of the Year. Mr McMillan was also CEO of BMG Direct, the North American music distribution division of Bertelsmann, A.G., and CFO/COO of Renaissance Solutions, a strategic consulting and technology services company. Mr McMillan holds a Bachelor of Arts degree in Economics from Stanford University, a Doctor of Law from Harvard Law School and a Masters of Business Administration from Harvard Business School.

Everett Neville

Everett Neville

Executive Vice President, Chief Value Officer
John Oyler

John Oyler

Chairman and Co-Founder

John Oyler is Chairman and Co-Founder, and has served as Chief Executive Officer and a member of our Board of Directors of BeiGene since 2010. From 2005 to 2009, Mr Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology-focused biopharmaceutical company. Mr Oyler began his career as a management consultant at McKinsey & Company. Mr Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.

Mary Rozenman

Mary Rozenman

Chief Financial and Chief Business Officer

Mary Rozenman has more than 15 years of scientific expertise, company building and transactions leadership in the biotechnology industry. She is currently Chief Financial Officer/ Chief Business Officer of insitro, a company applying machine learning to drug discovery and development. There, she leads strategic and operational functions including finance and accounting, strategy, business development, investor relations and corporate communications, as well as project and portfolio management. Prior to Insitro, she was Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics, where she led business development and partnerships with companies such as Regeneron/Sanofi and Nestlé Health Science, and raised more than $650 million in capital through a range of private and public transactions including leadership of the company’s 2015 IPO. Before Aimmune, she was venture investor at Longitude Capital focused on biotechnology and a junior partner at McKinsey & Co focused on pharmaceuticals and corporate finance. Dr Rozenman holds a PhD in Organic Chemistry and Chemical Biology from Harvard University and a BA in Biochemistry and Russian literature from Columbia University.

Leonard Schleifer

Leonard Schleifer

Co-Founder, President and CEO

Leonard Schleifer, MD, PhD, founded Regeneron in 1988 and has been a Director and its President and Chief Executive Officer since its inception. He served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Dr George Yancopoulos, has grown Regeneron from a tiny start-up into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine, and seven FDA-approved medicines. Dr.Schleifer has been recognized as one of Barron’s Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia. Dr Schleifer is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.

Susan Shiff

Susan Shiff

Senior Vice President, Center for Observational and Real-World Evidence

Susan Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, access and reimbursement scientists, health services researchers and others involved in health policy research with the goal of leading global strategic value evidence generation and access strategy development to optimize reimbursement and patient outcomes across Merck’s portfolio.

Prior to joining Merck, Dr Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics, and access and pricing. She has also led the global risk management group and US HEOR group at Roche and spent four years at the US Centers for Disease Control and Prevention (CDC).

Dr Shiff received her PhD degree from UCLA, and an MBA degree from Cornell University. She currently serves on the Institute for Clinical and Economic Review (ICER), Advisory Board and Methods Sub-Committee; Health Technology Assessment International (HTAi), Policy Advisory Board; the Innovation and Value Initiative (IVI), Panel of Health Advisors, the Academy of Managed Care Pharmacy (AMCP) Foundation Board, and the New Jersey Symphony Orchestra, Board of Trustees, Education, and Development Committees. She is also a Non-Executive Director of Synthace Ltd. In 2016, Dr Shiff was named one of the top 15 women in Biopharma by FiercePharma.

Suneet Varma

Suneet Varma

Global President, Rare Disease Business Unit

Suneet Varma is Global President, Rare Disease Business Unit, one of Pfizer’s fastest growing, high science units, which includes a broad gene therapy program.  Pfizer’s aspiration is to be the world’s leading innovator in rare disease by pioneering breakthroughs that have a profound impact on the lives of underserved patient populations.  Just prior to his current position, Mr Varma was Global President, Hospital Business Unit, one of Pfizer’s largest units which impacts the lives of over 200 million patients annually.   Recently he has been awarded as one of the 2019 Outstanding 50 Asian Americans in Business by the Asian American Business Development Center and currently sits on The Board of Trustees of Drew University.

Joanne  Waldstreicher

Joanne Waldstreicher

Chief Medical Officer
Johnson & Johnson

Joanne Waldstreicher, M.D., is Chief Medical Officer, Johnson & Johnson. In this role, she has oversight across pharmaceuticals, devices and consumer products for safety, epidemiology, clinical and regulatory operations transformation, collaborations on ethical science, and technology and R& D policies, including those related to trial transparency and compassionate access. She Chairs the R&D development pipeline review committee for Janssen, the pharmaceuticals group of Johnson & Johnson, and supports Device and Consumer Development committees. Dr Waldstreicher is also a Faculty Affiliate of the Division of Medical Ethics, Department of Population Health, New York University School of Medicine. Among her prior roles, she was responsible for late-stage development in neuroscience, cardiovascular disease and metabolism at Janssen. Before joining Johnson & Johnson in 2002, Dr Waldstreicher headed Endocrinology and Metabolism clinical research at Merck Research Laboratories, overseeing development programs in atherosclerosis, obesity, diabetes, urology and dermatology. She was honoured with the Key Innovator Award, among other distinctions. Dr Waldstreicher, received both the Jonas Salk and Belle Zeller scholarships from the City University of New York, and graduated Summa Cum Laude from Brooklyn College. She graduated Cum Laude from Harvard Medical School, completed her internship and residency at Beth Israel Hospital, and her endocrinology fellowship at Massachusetts General Hospital. She has received numerous awards and scholarships, and is an active scientific author. In 2016, the National Association of Female Executives named her Healthcare Champion of the Year.

Terry Wilcox

Terry Wilcox

Co-Founder and Executive Director
Patients Rising

As the Co-founder and Executive Director of Patients Rising, Terry Wilcox helps patients find their voice and become outspoken advocates for their healthcare.  She manages all of the day to day operations for the organization and is the visionary behind all of Patients Rising’s programs, including: Patients Rising University (education), Patients Rising Concierge (support), Institute for Patient Access & Affordability (research), and the policy and advocacy work of Patients Rising Now.  She has a track record of building coalitions with patients, caregivers, and medical professionals. A regular opinion writer on health policy and how it affects patients, she has been published in the Boston Globe, The Hill, Morning Consult, Crains NY, Real Clear Health, the American Thinker, among others.  Ms Wilcox’s career in patient advocacy was inspired by her mentor Selma Schimmel, considered by many as the “original” young adult survivor advocate. As Executive Director for Vital Options International, Ms Wilcox advanced Selma’s legacy at the non-profit cancer communication, education and advocacy organization. From 2008 to 2014, Ms Wilcox worked alongside Selma as Creative Director at Vital Options International and supervising producer for The Group Room.

Hui Wu

Hui Wu

Founder and CEO
iCCAMT; Venture Partner, Chareon Pokphand Asset Management

Hui Wu, PhD is the founder of the International Co-Innovation Center for Advanced Medical Technology (iCCAMT) in Shanghai. With partners Medical Valley GmbH, Robert Bosch GmbH and SinoPharm (#169 on the FORTUNE Global 500), iCCAMT builds bridges between international healthcare players and China markets. Dr Wu is also Chair and Managing Partner in the China region for the Steinbeis Foundation, a German organization that promotes sharing of knowledge between universities and industry. Additionally, Dr. Wu is Venture Partner at Charoen Pokphand (CP) Asset Management, a life sciences investment fund from CP Group, Thailand’s largest company, and Senior Advisor to the Chairman at CP Pharma, parent company of Sino Biopharmaceutical Ltd, which is listed on the Hong Kong Stock Exchange. Dr Wu previously served for several years as a vice division leader for AVIC International, a leading Chinese state-owned enterprise with annual revenue of over US$50bn. Dr Wu holds a BSc in Biology from Wuhan University in China, a Master’s degree in Biomedicine from Uppsala University in Sweden and a PhD in cancer genomics from the University of Heidelberg in Germany.


Chair (3)

Hannah Kuchler

Hannah Kuchler

US Pharma and Biotech Correspondent
Financial Times

Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York.  Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.

Mike DeLone

Mike DeLone

Principal, US Life Sciences Sector Leader
Sarah Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. 

Agenda - 29th Sep

  • 8:15am
    Registration & Breakfast
  • 9:00am
    Opening Remarks from the Chair
  • 9:05am
    Keynote Address/ Interview

    Stephen Hahn, Commissioner, U.S. Food & Drug Administration (FDA)

  • 9:20am
    Panel: Pharma Pricing and Politics: From Rhetoric to Action?

    Initial expectations that the industry’s laudable efforts to tackle the coronavirus pandemic might take the heat off legislators’ efforts to reform drug pricing may be short lived; a simmering debate on how to value and price vital COVID-19 vaccines and treatments could have far reaching consequences for how we approach the pricing of drugs in future, as well as for Washington’s appetite for reform. Recent pronouncements by President Trump, meanwhile, that he ‘has not forgotten drug pricing reform’ will ensure that the issue will likely remain central to the political debate in this 2020 election year and beyond.

    • What can we expect in terms of drug pricing reform in the run up to the November election and beyond? Will a post-pandemic economic slowdown increase pressure for pricing reform and accelerate the uptake of outcomes-based pricing?
    • How should COVID-19 vaccines and treatment with meaningful impact be valued and priced?
    • Will the debate over COVID-19 vaccine and drug pricing open the door for broader drug pricing controls?
    • What are the emerging solutions being considered to address the issue of rising drugs prices?

    Peter Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
    Leonard Schleifer, Co-Founder, President and Chief Executive Officer, Regeneron
    Terry Wilcox, Co-Founder and Executive Director, Patients Rising
    Tom Fezza, Partner Life Sciences and Health Care Strategy Advisor, Deloitte 

  • 10:05am
    Keynote Interview/ Address

    Alexander Hardy, CEO, Genentech

  • 10:20am
    Panel: Mission Critical: Unlocking the Potential of Real-World Evidence ( RWE) / Real-World Data (RWD)

    Real-World Evidence (RWE) is increasing in use and importance across the pharma and broader healthcare industry. Key drivers include the growing willingness to include RWE in regulatory decision-making, the extension of value-based pricing, as well as a mounting awareness of the strategic benefits RWE can bring in terms speedier and more efficient drug development, enhanced patient engagement and competitive edge in an ever more value driven, personalized healthcare system. A case in point is the fight against COVID-19, where RWD is being used to advance potential therapies to market at breakneck speed while more robust data is gathered through clinical trials. Yet many barriers - both internal and external - exist before the full potential of RWE/RWD can realised.

    • As the landscape for RWE continues to evolve, what are the implications for current infrastructure, governance, operating models, people and processes of pharma companies?
    • What are the learnings and insights of market leaders who have developed end-to-end RWE /RWD capabilities?
    • How is the data landscape evolving?

    Susan Shiff, Senior Vice President and Head of Center for Observational and Real-World Evidence (CORE), Merck
    Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi
    Everett Neville , Senior Vice President, Value Creation , Cigna  
    Joanne Waldstreicher, Chief Medical Officer, Johnson & Johnson

  • 11:05am
    Networking Coffee Break
  • 11:25am
    Keynote Address/ Interview

    Jessica Mega, Chief Medical and Scientific Officer, Verily Life Sciences

  • 11:40am
    Bridging a Pharma-Digital Divide? Unconventional Partnerships and Collaborations in Pharma

    Technology solutions have proven their worth in the battle with COVID-19, and as pharma companies navigate the digital terrain, they are increasingly working in close partnerships with players from the world of big tech and big data. Yet it is often remarked that an unspoken divide separates the ‘parallel worlds’ of pharma and tech, preventing closer alignment and realizing the full potential that such partnerships can offer. The ‘glacial pace of decision-making’ and siloed world of in pharma is often contrasted with the more ‘agile and open’ world of tech.

    • How real is the ‘cultural divide’ between pharma and data companies?  What have been the experiences of such partnership to date? How synergistic are the relationships?
    • How are pharma companies and their digital partners navigating challenges of IP, data rights, sharing and ownership and attributing value in such joint endeavours? How are partnership models evolving?
    • How vital are partnerships: could pharma ‘go it alone’ on AI and digital therapeutics?

    Mary Rozenman, Chief Financial and Chief Business Officer, Insitro
    Ofer Leidner, President and Co-Founder, Happify Health
    Rich Carter, Vice President, Chief Digital Officer Eli Lilly and Company
    Moderator: Mike DeLone, Principal, US Life Sciences Sector Leader, Deloitte

  • 12:20pm
    From ‘Patient Centricity’ to True Patient Collaboration: Insights from the Realm of Rare Diseases

    ‘Patient centricity’ has become the buzzword of the industry over recent years, and COVID-19 has highlighted the need to embrace a strategic approach to this important issue. The settings and ways the industry communicates with patients will be changed by the crisis. Patients are becoming increasingly involved in their healthcare, and ever more sophisticated in their interactions and collaborations with the industry. Meanwhile, the once rarefied world of patient engagement is still evolving with patients becoming data owners, curators, research funders, as well as influencing the direction of pharma R&D. Those involved in development of drugs and treatment of rare diseases have long experience of building enduring relationships with patients through strong commitment to patient disease communities, building disease awareness and meeting their changing needs. And they have witnessed first-hand the changes in the patient landscape and have been successfully harnessing the benefits meaningful engagement brings. Here we hear from early pioneers of patient centricity from the realm of rare diseases, and from their patient-partners on the implications of the new rules of patient engagement for both rare diseases and for the wider industry.

    William Lewis, Chairman and CEO, Insmed
    Kimberly Haugstad, CEO, Global Genes
    Margaret Anderson, Managing Director, Deloitte

  • 12:50pm
    Networking Lunch
  • 1:50pm
    Keynote Address/Interview

    Liz Barrett, CEO, UroGen Pharma

  • 2:05pm
    Panel: New Approaches for a New Age of Mental Health

    The lockdowns and social isolation which have been salient feature of the coronavirus pandemic have served to accentuate a problem which was already placing a heavy burden on the US healthcare system. Over 46 million Americans suffer mental illness, yet difficulties experienced in gaining access to treatment specialists and a dearth of new psychiatric drugs has left patients with ever more limited treatment options. The cost and complexity of research in the field of mental illness has seen the withdrawal of big pharma from the field of psychiatric drug research over the past decades. Yet new research in the field of genomics and mental health and in emerging areas to include immunemodality drugs, psychedelics and beyond, as well as new efforts to better understand the biology of the brain and mental illness hold the promise of new drugs in the future.

    Meanwhile, a new wave of apps and other digital interventions are rapidly changing the way mental health care is delivered, extending delivery beyond pills and traditional, in-person sessions to offer around-the-clock support from remote physicians or tech-driven tools that reach the patient wherever they are. Healthcare providers and pharma companies alike are looking increasingly to provide digital mental health offerings, often in partnership with start-ups.

    • What might be the next leap forward in psychiatric pharmacology?
    • What is the potential for genomics in mental health?
    • What are the advances in our understanding of biology of the brain and mental health which hold the promise for new drugs?
    • What is the potential and the challenges (e.g dealing with high-risk scenarios) with the new generation of digital apps and treatments?

    Florian Brand, Co-Founder and CEO, ATAI Life Sciences
    Oren Frank, Co-Founder and CEO, Talkspace
    Julia Hoffman, VP, Behavioural Health, Livongo Health
    Husseini Manji, Global Therapeutic Head for Neuroscience, Janssen Research & Development

  • 2:45pm
    Keynote Address/Interview

    George McMillan, Chief Commercial Officer, ICON

  • 3:00pm
    Networking Coffee Break
  • 3:20pm
    Panel: Leader or Follower? Tracking China's Pharma Growth

    China is stepping up its investment in life sciences and is aiming to take a lead in drug development, AI, gene editing and gene therapies. It is also now the second largest pharmaceuticals market in the world and is set to be the first within 7-10 years. Recent moves by the industry regulator are paving the way for faster drug approvals and greater access for patients to advanced therapies.

    Meanwhile, China is embracing digital at a pace which eclipses the efforts in most other countries and lacking the burden of legacy primary health care systems, is creating innovative new treatment and service models.

    John Oyler, CEO, BeiGene
    Hui Wu, Venture Partner, Chareon Pokphand Asset Management  

  • 3:50pm

    Christopher Hansung Ko, President, CEO and Chairman of the Board, Samsung Bioepis

  • 4:05pm
    The Future of Cell and Gene Therapies

    Innovation will remain the cornerstone of the industry in a post-pandemic world and the excitement surrounding the potential of cell and gene therapies continues with important new developments underway. Advances in genomics continue to inform the search for effective COVID-19 treatments. And after developing the first gene therapies for rare diseases, biotech companies are seeking to extend gene treatments to common illnesses affecting millions of people, providing new competition for big pharma in the process. Meanwhile, with the advent of the first human in-body gene editing, we are entering a new stage in the gene editing revolution that could lead to more diseases being treated or cured with this technology. However, many questions remain unanswered.

    • The new therapies look transformational, but will they be commercially successful for pharma given the manufacturing, administration, reimbursement and other complexities?
    • How can we industrialize personalisation to ensure sustainable patient access to advanced therapies?
    • How could the ‘engineering’ - based approach of gene editing potentially transform the business of pharma?
    • Can the safety and ethical concerns surrounding gene editing be addressed? Where do we draw the line between risk and opportunity?

    Shabbir Dahod, CEO, TraceLink
    David Lennon, President, AveXis
    Suneet Varma, Global President, Rare Disease Business Unit, Pfizer
    Natalie Kofler, Founder, Editing Nature
    Sandy Macrae, President and Chief Executive OfficerSangamo Therapeutics

  • 4:55pm
    Closing Remarks from the FT Chair

Companies in attendance in 2019

Sanofi • FDA • Eisai • Bayer • AstraZeneca • Novartis Pharmaceuticals • Mylan • Otsuka • GlaxoSmithKline • Eli Lilly • Pfizer • National Pharmaceutical Council • Takeda • UCB • Janssen • Vitruvian Biomedical • Bristol Myers Squibb • BioMarin Pharmaceutical Inc • Aquestive Therapeutics • Johnson & Johnson • Ibex Biosciences • Bound Therapeutics LLC • Horizon Pharma • Spark Therapeutics • Celgene • Regeneron Pharmaceuticals • CONTINUUS Pharmaceuticals and many others.



The FT US Pharma & Biotech Summit will be attended by CEOs, CFOs, CTOs CIOs, Head of R&D, Chief Medical Officers, Chief Strategy Officers, Chief Digital Officers, Market Access and Pricing, Chief Business Officers and other senior-level executives in the following sectors:

  • Pharmaceutical & Biotechnology Companies
  • Pharmaceutical Wholesalers/PBMs
  • CROs
  • Healthcare insurers and government payers
  • Regulators
  • Government healthcare departments and agencies
  • IT, big data and analytics providers
  • Medical Device Manufacturers
  • Investment bankers, private equity and VCs
  • Patient representatives and health-related NGOs


  • Gain access to 250 executives and leaders from across the US pharmaceutical industry;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames

Head of Portfolio

M: +44 (0)791 329 2038



Why attend

  • Gain insights into the healthcare reforms being proposed by US Presidential candidates and how they might affect pharma pricing and risk
  • Hear how payer’ perspectives on value is evolving
  • Discuss the challenges and opportunities of unconventional partnerships in pharma and the myth and reality of pharma’s digital divide
  • Debate whether governments should play a bigger role in drug development as ROI diminishes, shortages increase and price of drugs continue to rise
  • Get the inside story on whether China will be a leader or follower in life sciences as the county’s level of ambition and innovation increases
  • Discover the latest development in gene editing and have your say on where we should draw the line between risk and opportunity


The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Global sponsor (1)

About Life Sciences and Health Care at Deloitte

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

Global Clinical Research Partner (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 40 countries and has approximately 14,500 employees. For further information please visit  Follow @iconplc on Twitter.

Lead Sponsor (2)

Associate Sponsors (4)

ATAI Life Sciences AG is a global biotech platform and company builder working to address significant unmet medical need rooted in a lack of innovation in neuropsychiatry. Based in Berlin, London and New York, its vision is to cure mental health disorders, enabling people to live healthier and happier lives.

Livongo offers a whole person platform that empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention, and behavioral health. Livongo pioneered the new category of Applied Health Signals to silence Noisy Healthcare™. Our team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized and timely health signals. The Livongo approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions.

TraceLink is a network-based platform company that leverages its digital supply network and digital network platform to bend the supply chain around the patient. Through its industry-leading digital supply network, the TraceLink Digital Network Platform can enable seamless data sharing and process orchestration across the entire healthcare industry, enabling the creation of a real-time, patient-driven supply network to ensure that every patient gets the medicines they need, when they need them, safely and securely.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, because patients deserve better options. Drawing on our innovative RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs, we enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s approved Jelmyto™ (mitomycin) for pyelocalyceal solution, and pipeline treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively.


730 Third Avenue
New York 10017

United States of America

Tel: (646) 854-7950


Contact Us

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times